Funded Startups in Schlieren
Disclosed round sizes in Schlieren are concentrated below $25M, with arcoris bio’s $8M (Seed, 2025-11-03) acting as the largest disclosed amount in this 21…
Disclosed round sizes in Schlieren are concentrated below $25M, with arcoris bio’s $8M (Seed, 2025-11-03) acting as the largest disclosed amount in this 21-row slice; nearly all other disclosed rounds sit at $25M or lower, while several entries are undisclosed (e.g., 8links on 2026-06-15; Pregnolia on 2026-02-25; HeiQ Materials on 2023-07-06; Fixposition on 2022-12-21; Avelo on 2022-12-12). A second pattern is temporal: the most recent entries cluster in 2026, with multiple rounds dated 2026-06-15 (8links, Immitra Bio), 2026-04-17 (Forgis), and 2026-02-25 (Pregnolia). Sector-wise, biotechnology is the largest share in the displayed set (8 of 21 entries), and funding classifications are frequently unspecified, with “Series Unknown” in 8 of 21 rows and “undisclosed” amounts in 5 of 21 rows.
Across stages, disclosed financings range from small grants/debt (Topadur Pharma’s $620K grant on 2022-06-07; ProteoMediX’s $3M debt financing on 2021-09-24) up to large biotech financings such as ImmunOs Therapeutics’ $11M Series C on 2024-09-17 and Memo Therapeutics’ $25M Series B on 2022-02-16. The date window spans 2021-06-09 (VirtaMed) through 2026-06-15 (8links and Immitra Bio), with the newest disclosed amount at $190K for Immitra Bio (2026-06-15).
Most recent rounds
21 shownRelated listings
Frequently asked
What’s the largest disclosed round in Schlieren here, and how does it compare to the rest of the disclosed amounts?
The largest disclosed amount is arcoris bio’s $8M (Seed) on 2025-11-03. In this slice, other disclosed rounds are generally lower, including ImmunOs Therapeutics at $11M (2024-09-17) and Memo Therapeutics at $25M (2022-02-16) that remain below the largest disclosed ceiling defined by arcoris bio within the displayed highest disclosed value context; several other entries are not comparable on size due to “undisclosed” amounts (e.g., 8links on 2026-06-15, Pregnolia on 2026-02-25).
Are there clear time clusters among the most recent Schlieren financings?
Yes. Four of the most recent entries fall in 2026 (2026-06-15: 8links and Immitra Bio; 2026-04-17: Forgis; 2026-02-25: Pregnolia), creating a tight recent window compared with older rounds like VirtaMed’s $600K on 2021-06-09.
Which sectors appear most often, and what does that imply about where deals concentrate?
Biotechnology dominates with 8 of 21 entries (e.g., Immitra Bio on 2026-06-15; arcoris bio on 2025-11-03; ImmunOs Therapeutics on 2024-09-17; Memo Therapeutics on 2022-02-16). Energy and Financial Services appear multiple times as well (Energy: 8links 2026-06-15, Pexapark 2023-09-26; Financial Services: numarics 2023-07-06, TONI Digital 2023-01-10), but neither matches biotech’s share.
How much of this Schlieren list is hard to size due to missing amounts or classifications?
“Series Unknown” appears in 8 of 21 rows (including 8links on 2026-06-15 and Forgis on 2026-04-17), while “undisclosed” amounts appear in 5 of 21 rows (8links, Pregnolia, HeiQ Materials, Fixposition, Avelo). That combination means a material portion of entries can’t be compared by disclosed round size alone (e.g., HeiQ Materials is undisclosed on 2023-07-06).
Are there notable outliers in financing type or magnitude that stand out for follow-up?
ProteoMediX is a funding-type outlier with $3M labeled “Debt Financing” on 2021-09-24, contrasted with equity-style rounds such as ImmunOs Therapeutics’ $11M Series C on 2024-09-17 and Memo Therapeutics’ $25M Series B on 2022-02-16. On the magnitude side, the disclosed range includes small checks like SalesPlaybook’s $660K Seed on 2022-09-14 and larger disclosed rounds like Memo Therapeutics on 2022-02-16.
What stage mix is visible for disclosed rounds in Schlieren (and where do the strongest labeled rounds sit)?
Within labeled stages, “Series C” shows up multiple times (ImmunOs Therapeutics $11M on 2024-09-17; Pexapark $21M on 2023-09-26), and “Series B” also appears more than once (TONI Digital $13M on 2023-01-10; Memo Therapeutics $25M on 2022-02-16). Smaller early-stage labeled deals are visible too, like IMAI MedTech’s $170K Pre-Seed on 2024-06-17 and SalesPlaybook’s $660K Seed on 2022-09-14.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.